Project Grant R01EY036107
Award Date
7/1/24
Completion Date
6/30/28
Dollars Obligated
$617K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Notre Dame, IN 46556, USA
Similar Awards
This Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $1,066,178 to Tavo Biotherapeutics, Inc. (operating as Oculo Therapy LLC) to support late-stage preclinical development and GMP production of a novel extended-release intraocular pressure (IOP)-lowering formulation for the treatment of glaucoma. The funding will enable critical IND-enabling studies for this first-in-class drug candidate using the FDA-approved drug pregabalin as...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), will support research to investigate the molecular mechanisms underlying trabecular meshwork cell loss and cytotoxicity caused by mutant myocilin misfolding in glaucoma. The $447,479 award to Georgia TECH Research Corp will enable a 5-year research project to: 1) Screen a yeast gene deletion library to identify genes that can restore cell viability when mutant myocilin is expressed,...
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...
This federal Project Grant award of $362,415 from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to investigate the role of the orexin neurotransmitter system in regulating intraocular pressure (IOP) and its potential implications for glaucoma treatment. The research aims to: 1) examine the influence of the brainstem raphe pallidus on IOP elevations induced by stimulation of the dorsomedial hypothalamus/perifornical region, 2) assess the...
This federal Project Grant award, totaling $496,633, was awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867). The grant supports a research project at Duke University to investigate the role of glypicans, specifically glypican-4 (GPC4), in trabecular meshwork function, intraocular pressure regulation, and the development of glaucoma. The project aims to uncover the molecular mechanisms by which augmented GPC4 expression and secretion may dysregulate Wnt...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides $234,000.00 to Oregon Health & Science University (OHSU) to research restoring intraocular pressure (IOP) homeostatic function in glaucomatous eyes. The project aims to use senolytic treatments and senoreversion therapies, either alone or in combination with stem cell transplantation, to address IOP dysregulation and vision loss associated with glaucoma. The award...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), supports research to investigate the combined effects of aging and elevated intraocular pressure (IOP) on the development of glaucoma and retinal ganglion cell (RGC) transcriptomics, as well as determine how transient epigenetic reprogramming using a gene therapy can reverse these age- and glaucoma-specific transcriptomic changes and restore visual function. The total award...
This $218,068 Project Grant awarded by the National Eye Institute (NEI) under CFDA Program 93.867 "Vision Research" aims to structurally and biochemically characterize wild-type lysyl oxidase-like 1 (LOXL1) protein and variants associated with pseudoexfoliation glaucoma (XFG). The project will examine how specific LOXL1 variants impact the protein's structure, processing, interactions, and catalytic activity to further understanding of how LOXL1 contributes to XFG, the most common form...
This Project Grant award, totaling $526,841, was provided by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) to Vanderbilt University Medical Center (VUMC). The objective is to investigate the potential role of cyclic guanosine monophosphate (cGMP) signaling in countering retinal ganglion cell (RGC) degeneration in glaucoma. The research aims to discern the effects of cGMP signaling on astrocyte-vascular networks, RGC mitochondrial function, and...